The company says preclinical trials demonstrate its signature molecule can help prevent cell damage that can lead to ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

Telomir Pharmaceuticals , Inc. (NASDAQ:TELO), a $141 million market cap biopharmaceutical company engaged in age-reversal science, has announced significant preclinical study results today, indicating ...

Telomir announced results from its recent preclinical studies conducted in human cell lines. These studies demonstrated the ability of ...

First-year student documents emotional 6-hour journey from Polokwane to University of Venda, sharing family moments and campus arrival experiences.